Deerfield Management Company, L.P. (Series C) Protara Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$13.75 - $23.86 $10.8 Million - $18.7 Million	-782,670 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$16.76 - $31.89 $5.87 Million - $11.2 Million	350,000 Added 80.89%	782,670 $13.2 Million
Q2 2020 Aug 14, 2020	BUY	$22.0 - $60.7 $9.52 Million - $26.3 Million	432,670 New	432,670 $12.7 Million

Others Institutions Holding TARA

# of Institutions

Shares Held

10.7M

Call Options Held

Put Options Held

1.8K

Ra Capital Management, L.P. Boston, MA

1.9M
Shares

$12 Million
0.05% of portfolio
Opaleye Management Inc. Boston, MA

1.68M
Shares

$10.6 Million
0.56% of portfolio
Stem Point Capital LP New York, NY

943K
Shares

$5.97 Million
0.52% of portfolio
Woodline Partners LP San Francisco, CA

852K
Shares

$5.39 Million
0.01% of portfolio
Boxer Capital, LLC San Diego, CA

812K
Shares

$5.14 Million
0.08% of portfolio

View Full List

About Protara Therapeutics, Inc.

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $71.3M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

More about TARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account